Key findings of the study include:
Most people with PD (78%) are living with excessive symptoms that are considered out of target, including high levels of bradykinesia (slowness and freezing), dyskinesia (involuntary movements) and tremor (constant shaking).
With the use of targets and objective measurements reported with the PKG™ system, treatment options were improved in more than half (58%) of the 77 participants who completed the study.
Ad Statistics
Times Displayed: 112843
Times Visited: 6729 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
A number of people enrolled in the study (25%), mostly patients with more severe PD, were hospitalised, unable to travel or otherwise unable to complete the study.
After considering the PKG™ and targets, device assisted therapies, such as Deep Brain Stimulation or infusional therapies, were recommended for 19% of patients completing the study:
Device assisted therapies were unlikely to have been considered in most of these cases.
Most significantly, targets and PKG monitoring led to changes in oral medication, which improved quality of life and clinical outcomes of 43% of patients who completed the study (33 patients):
10-point improvement in quality of life as assessed by the PD Questionnaire (PDQ-39) (p<0.08).
8-point improvement in clinical symptoms as measured by Total UPDRS clinical scales (p<0.0009).
John Schellhorn, CEO Global Kinetics Corporation, said, “To date, Global Kinetics has supported clinical decisions for doctors who treat patients with Parkinson’s disease across 17 countries with more than 3,000,000 hours of clinical data from our FDA-cleared, CE-marked PKG™ wearable device. This study provides the foundation for a new era in the treatment and management of Parkinson’s, one in which targetless management is replaced by objective and continuous targets and measurement that can improve the care and outcomes for every person with Parkinson’s.”
About Global Kinetics Corporation Ltd.
Global Kinetics Corporation Ltd. is committed to improving the lives of those with Parkinson’s disease with advanced medical technologies. The company was formed in 2007 to commercialise its lead product, the Personal KinetiGraph™ (PKG™), also known as the Parkinson’s KinetiGraph™ outside the USA. Developed in conjunction with the world-renowned Florey Institute of Neuroscience & Mental Health in Melbourne, Australia, the Personal KinetiGraph™ enables the precise monitoring, quantification and reporting of movement symptoms in Parkinson’s. Global Kinetics Corporation, a privately held company, is headquartered in Melbourne, Australia with offices in London UK, Minneapolis and Portsmouth, NH USA.
Back to HCB News
